Company Profile
electroCore Stock Price, News & Analysis
- Ticker:
- ECOR
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
6.70 USD (+2.60%)
Close
Last updated: August 6, 2026
78.4M USD
Market cap
Why the stock is moving
The latest monitored company update is “electroCore Announces Second Quarter 2026 Financial Results.” The corresponding closing-price reaction is not yet available.
Company overview
Noninvasive Neuromodulation
electroCore develops handheld bioelectronic devices that stimulate the vagus nerve without surgery. Its products are used across prescription and consumer channels.
gammaCore
gammaCore is a prescription noninvasive vagus-nerve-stimulation device used for headache disorders. A major commercial channel is the U.S. Department of Veterans Affairs.
Quell and Truvaga
The Quell franchise addresses fibromyalgia and chronic pain through wearable neurostimulation, while Truvaga is marketed directly to consumers for wellness applications.
Clinical Expansion
electroCore is also supporting studies of gammaCore in additional neuropsychiatric settings, including adjunctive treatment of post-traumatic-stress symptoms.
Future catalysts
electroCore’s catalysts are gammaCore adoption, migraine and cluster-headache penetration, and any broader neuromodulation update. The market will care about recurring usage and payer support.
Recent news
- 01
electroCore Announces Second Quarter 2026 Financial Results
Source: electroCore
- 02
electroCore to Participate in Upcoming Investor Conferences
Source: electroCore
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of electroCore (ECOR)?
electroCore (ECOR) most recently closed at 6.70 USD, a +2.60% move versus the previous session.
What is the market cap of electroCore (ECOR)?
electroCore currently has a market capitalization of 78.4M USD on BioPharmSignal.
What does electroCore do?
Noninvasive Neuromodulation electroCore develops handheld bioelectronic devices that stimulate the vagus nerve without surgery. Its products are used across prescription and consumer channels. gammaCore gammaCore is a prescription noninvasive vagus-nerve-stimulation device used for headache disorders. A major commercial channel is the U.S. Department of...
On which exchange is ECOR stock listed?
electroCore (ECOR) is associated with NASDAQ, United States, Biopharma.
What is Noninvasive?
Noninvasive Neuromodulation electroCore develops handheld bioelectronic devices that stimulate the vagus nerve without surgery.
Which conditions is electroCore targeting with Noninvasive?
Noninvasive Neuromodulation electroCore develops handheld bioelectronic devices that stimulate the vagus nerve without surgery. Its products are used across prescription and consumer channels. gammaCore gammaCore is a prescription noninvasive vagus-nerve-stimulation device used for headache disorders. A major commercial channel is the U.S. Department of...
How does electroCore describe recent progress with Noninvasive?
electroCore’s catalysts are gammaCore adoption, migraine and cluster-headache penetration, and any broader neuromodulation update. The market will care about recurring usage and payer support.
What is Neuromodulation?
Noninvasive Neuromodulation electroCore develops handheld bioelectronic devices that stimulate the vagus nerve without surgery.